ClinicalTrials.Veeva

Menu
C

Clinical Research of Gastonia | Gastonia, NC

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

BLU-5937
Astegolimab
JZP-258
Tiotropium
Pitolisant
Dupilumab
TAK-994
SUVN-G3031
AD109
S-600918

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

14 of 40 total trials

A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-2)

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

Enrolling
Refractory Chronic Cough
Drug: BLU-5937
Drug: Placebo

The primary objective of this study is to assess the long-term safety and effectiveness of pitolisant in patients with idiopathic hypersomnia (IH) wh...

Active, not recruiting
Idiopathic Hypersomnia
Excessive Daytime Sleepiness
Drug: Pitolisant

HZNP-HZN-825-303 (HARBOR) comprises of 2 parts. Part 1 (Core Phase) is a randomized, double-blind, placebo-controlled, repeat-dose, multicenter trial...

Active, not recruiting
Idiopathic Pulmonary Fibrosis
Drug: HZN-825
Drug: Placebo

This study is comparing the medicine RYBELSUS® to other medicines in people with type 2 diabetes who need extra treatment. All medicines used in this...

Active, not recruiting
Diabetes Mellitus, Type 2
Drug: oral glucose-lowering medications (commercially available)
Drug: semaglutide

This is a Phase 2/3 study that comprises 5 substudies designed to evaluate the efficacy, safety, and tolerability of oral etrasimod as therapy in adu...

Enrolling
Crohn's Disease
Drug: Placebo
Drug: Etrasimod

This study will evaluate the efficacy and safety of astegolimab compared with placebo in participants with chronic obstructive pulmonary disease (COP...

Enrolling
Chronic Obstructive Pulmonary Disease (COPD)
Drug: Astegolimab
Drug: Placebo
Status recently updated

This study will evaluate the efficacy, safety, and pharmacokinetics of astegolimab in combination with standard of care chronic obstructive pulmonary...

Enrolling
Active, not recruiting
Chronic Obstructive Pulmonary Disease
Drug: Placebo
Drug: Astegolimab

The purpose of this study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmo...

Enrolling
Chronic Obstructive Pulmonary Disease
Drug: Astegolimab

This study will assess the safety and efficacy of JZP258 (XYWAV) on sleepiness, polysomnography, and functional outcomes in patients with idiopathic...

Enrolling
Idiopathic Hypersomnia
Narcolepsy
Drug: JZP258 (XYWAV)

This is a Phase 2b, global, multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the efficacy, saf...

Enrolling
Asthma
Drug: Placebo
Drug: Lunsekimig

This is a Phase 3 Randomized Double-Blind Placebo-Controlled 1-year Parallel-Arm Study to Compare a Fixed Dose Combination of AD109 to Placebo in Obs...

Active, not recruiting
OSA
Drug: Placebo
Drug: AD109

Primary Objective:To evaluate the efficacy of dupilumab administered every 2 weeks in patients with moderate or severe Chronic Obstructive Pulmonary...

Active, not recruiting
Chronic Obstructive Pulmonary Disease
Drug: Placebo
Drug: Inhaled Long-Acting Muscarinic Antagonist

This is an interventional, randomized, parallel group, treatment, Phase 3b/4, double blind, 2-arm study to assess the effect of dupilumab compared to...

Enrolling
Asthma
Drug: Placebo
Drug: Dupilumab

This is a multicenter, randomized, double-blind, placebo-controlled, dose-response trial in patients with chronic stable Heart Failure (HF) and reduc...

Enrolling
Reduced Ejection Fraction
Heart Failure
Drug: INL1
Other: Placebo

Trial sponsors

Boehringer Ingelheim logo
Jazz Pharmaceuticals logo
Sanofi logo
B
H
Roche logo
Takeda logo
V
Amgen logo
Apnimed logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems